

CITATION REPORT

List of articles citing

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

DOI: 10.1182/blood-2008-09-176818
Blood, 2009, 113, 4829-33.

Source: <https://exaly.com/paper-pdf/45385142/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
210	The integrated approach to the diagnosis of hematological malignancies. 111-126		1
209	Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. 2009 , 27, 5418-24		317
208	Essential thrombocythemia: past and present. 2009 , 4, 381-8		21
207	Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?. <i>Blood</i> , 2009 , 114, 759-63	2.2	118
206	Current world literature. 2010 , 22, 664-8		
205	Advances in understanding and management of polycythemia vera. 2010 , 22, 636-41		7
204	Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. <i>Blood</i> , 2010 , 116, 1051-5	2.2	46
203	Subclinical hypercortisolism among polycythemia vera patients. 2010 , 49, 1277-80		
202	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 2010 , 95, 1435-8		37
201	Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant. 2010 , 85, 290-3		1
200	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. 2010 , 85, 288-90		50
199	Is the JAK2(V617F) mutation detectable in healthy volunteers?. 2010 , 85, 287-8		28
198	Detection of hereditary hemochromatosis and biochemical iron overload in primary care: a multicenter case finding study in Spain. 2010 , 85, 294-6		4
197	Development of Libfller's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. 2010 , 85, 296-9		
196	Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions. 2010 , 85, 300-1		1
195	ASH 2009 meeting reportTop 10 clinically oriented abstracts in acute leukemia. 2010 , 85, 277-280		0
194	ASH 2009 meeting reportTop 10 clinically oriented abstracts in lymphoma. 2010 , 85, 280-283		

193	ASH 2009 meeting report—Top 10 clinically oriented abstracts in chronic myeloid leukemia. 2010 , 85, 283-286		0
192	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. 2010 , 148, 961-3		115
191	A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. 2010 , 150, 446-55		174
190	Myeloproliferative neoplasms. 283-306		
189	Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. 2010 , 2010, 129-34		17
188	The renaissance of interferon therapy for the treatment of myeloid malignancies. <i>Blood</i> , 2011 , 117, 4706-15	153	
187	JAK2 inhibitors: are they the solution?. 2011 , 11 Suppl 1, S28-36		5
186	JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 2011 , 2, 21-32		63
185	New JAK2 inhibitors for myeloproliferative neoplasms. 2011 , 20, 961-72		18
184	Emerging treatments for essential thrombocythemia. 2011 , 2, 151-9		2
183	Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. 2011 , 23, 609-16		29
182	Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. 2011 , 2011, 536062		60
181	Targeting myeloproliferative neoplasms with JAK inhibitors. 2011 , 18, 105-10		30
180	Recombinant interferon- γ may retard progression of early primary myelofibrosis: a preliminary report. <i>Blood</i> , 2011 , 117, 6669-72	2.2	104
179	Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes. 2011 , 50, 2557-61		3
178	The European LeukemiaNet: achievements and perspectives. 2011 , 96, 156-62		12
177	Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. 2011 , 152, 81-8		55
176	Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. 2011 , 152, 413-9		19

175	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. 2011 , 10, 127-40		229
174	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 2011 , 29, 761-70		589
173	Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha. 2011 , 90, 233-4		4
172	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. 2011 , 90, 939-46		7
171	JAK2 inhibitors: what's the true therapeutic potential?. 2011 , 25, 53-63		61
170	JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. <i>Leukemia Research</i> , 2011 , 35, 177-82	2.7	48
169	Update on JAK2 Inhibitors in Myeloproliferative Neoplasm. 2011 , 2, 61-71		2
168	Management of essential thrombocythemia. 2011 , 2011, 215-21		33
167	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. 2012 , 3, 341-54		36
166	Experience with pegylated interferon α 2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. 2012 , 97, 1570-3		69
165	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. 2012 , 8, 575-93		3
164	Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. 2012 , 47, 342-51		118
163	Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?. 2012 , 26, 1148-9		9
162	Current treatment practices for essential thrombocythemia: survey results from European hematologists/oncologists. 2012 , 17, 187-92		1
161	Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. 2012 , 19, 4399-413		71
160	Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. 2012 , 97, 538-42		26
159	Essential thrombocythemia: new advances in an old disease. 2012 , 2, 603-614		1
158	How I treat polycythemia vera. <i>Blood</i> , 2012 , 120, 275-84	2.2	64

157	Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. <i>Blood</i> , 2012 , 119, 1363-9	2.2	156
156	How to manage essential thrombocythemia. 2012 , 26, 875-82		23
155	Front-line therapy in polycythemia vera and essential thrombocythemia. 2012 , 26, 205-11		48
154	Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. 2012 , 12, 70-5		13
153	Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. <i>Leukemia Research</i> , 2012 , 36, 1500-4	2.7	35
152	Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. 2012 , 29, 2388-95		9
151	Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. 2012 , 18, 1446-54		19
150	Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia. 2012 , 91, 1555-62		8
149	Therapy with JAK2 inhibitors for myeloproliferative neoplasms. 2012 , 26, 1083-99		16
148	Influence of interferon- α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B. 2012 , 2,		
147	Janus kinase inhibitors: jackpot or potluck?. 2012 , 6, e13		
146	How to manage children and young adults with myeloproliferative neoplasms. 2012 , 26, 1452-7		28
145	Treatment of polycythemia vera with imatinib mesylate. <i>Leukemia Research</i> , 2012 , 36, 156-62	2.7	9
144	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. 2012 , 157, 426-37		18
143	Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. 2012 , 118, 870-7		8
142	A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. 2013 , 162, 498-508		58
141	A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. 2013 , 161, 688-94		91
140	Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. 2013 , 92, 771-5		21

139	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon β a. <i>Blood</i> , 2013 , 122, 893-901	2.2	156
138	[Treatment of essential thrombocythemia]. 2013 , 141, 260-4		3
137	Anagrelide hydrochloride for essential thrombocythemia. 2013 , 1, 1049-1062		
136	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013 , 122, 1395-8	2.2	218
135	Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide. <i>Leukemia Research</i> , 2013 , 37, 917-21	2.7	19
134	Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. <i>Leukemia Research</i> , 2013 , 37, 1041-5	2.7	72
133	Polycythemia vera: current pharmacotherapy and future directions. 2013 , 14, 609-17		14
132	Thrombocythémie essentielle. 2013 , 8, 1-11		
131	Pharmacological management of essential thrombocythemia. 2013 , 14, 1295-306		3
130	[Diagnosis and therapy of polycythemia vera in the era of JAK2]. 2013 , 138, 331-6		1
129	Polycythemia vera: can we do better?. 2013 , 14, 687-9		1
128	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. <i>Blood</i> , 2013 , 121, 4778-81	2.2	159
127	JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. 2013 , 98, e135-7		27
126	Givinostat for the treatment of polycythemia vera. 2014 , 2, 841-850		1
125	Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?. 2014 , 55, 2706-11		4
124	Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. 2014 , 99, 679-87		17
123	Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. 2014 , 55, 2685-90		17
122	Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. 2014 , 92, 127-36		6

121	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 2014 , 120, 513-20		139
120	Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFN β treatment. 2014 , 28, 460-3		10
119	Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. 2014 , 93, 1965-76		26
118	Interferon β gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. <i>Leukemia Research</i> , 2014 , 38, 1177-83	2.7	21
117	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. <i>Leukemia Research</i> , 2014 , 38, 816-21	2.7	10
116	Effect of busulfan on JAK2V617F allele burden. 2014 , 99, e44		1
115	How I treat polycythemia vera. <i>Blood</i> , 2014 , 124, 3212-20	2.2	63
114	Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal. 2015 , 5, 643-651		
113	Ropeginterferon alfa-2b, a novel IFN β , induces high response rates with low toxicity in patients with polycythemia vera. <i>Blood</i> , 2015 , 126, 1762-9	2.2	106
112	Clinical and molecular response to interferon- β therapy in essential thrombocythemia patients with CALR mutations. <i>Blood</i> , 2015 , 126, 2585-91	2.2	104
111	Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. 2015 , 5, 3		12
110	Budd-Chiari syndrome complicating essential thrombocythemia in an adolescent: favorable outcome of TIPS procedure. 2015 , 26, 691-4		2
109	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). 2015 , 62, 1717-24		72
108	Guidelines for the management of myeloproliferative neoplasms. 2015 , 30, 771-88		17
107	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. 2015 , 90, 288-94		38
106	Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2015 , 26 Suppl 5, v85-99		71
105	Ruxolitinib for treatment of polycythemia vera. 2015 , 3, 1085-1096		0
104	Novel and emerging therapies for the treatment of polycythemia vera. 2015 , 8, 101-13		4

103	Genomic Applications in Hematologic Oncology. 2015 , 297-319	
102	Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. 2015 , 16, 1185-94	3
101	Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor. 2015 , 94, 1237-9	3
100	Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. 2015 , 36, 3-16	15
99	Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide. 2015 , 8, 819-35	
98	Ruxolitinib: A Review in Polycythaemia Vera. 2015 , 75, 1773-81	13
97	New Therapeutic Approaches in Polycythemia Vera. 2015 , 15 Suppl, S27-33	9
96	Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. 2015 , 373, 920-8	135
95	Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. 2015 , 33, 3953-60	51
94	Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. 2015 , 94, 717-9	1
93	Target hematologic values in the management of essential thrombocythemia and polycythemia vera. 2015 , 94, 4-11	14
92	Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). 2015 , 29, 20-6	33
91	[Blood count results from hypertensive patients seen in laboratory of CHU-HJRB Antananarivo in 2013]. 2016 , 23, 49	1
90	Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. 2016 , 11, e0165336	29
89	Management of polycythaemia vera: a critical review of current data. 2016 , 172, 337-49	18
88	Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. 2016 , 14, 1613-1624	2
87	Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. 2016 , 142, 2041-9	9
86	Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. 2016 , 25, 1393-1403	21

85	[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. 2016 , 59, 444-53		0
84	Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. 2016 , 172, 786-93		41
83	Interferon- α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. 2016 , 97, 83-92		22
82	How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. 2016 , 11, 356-67		10
81	Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?. 2016 , 12, 739-49		1
80	Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. 2016 , 95, 719-32		3
79	Minimal residual disease after long-term interferon- α 2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. 2016 , 57, 348-354		28
78	Can pegylated interferon improve the outcome of polycythemia vera patients?. 2017 , 10, 15		12
77	Polycythemia Vera Management and Challenges in the Community Health Setting. 2017 , 92, 179-189		8
76	Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. 2017 , 4, e165-e175		74
75	Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α treated polycythemia vera patients. 2017 , 102, e97-e99		6
74	A phase 1 study of the Janus kinase 2 (JAK2) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. <i>Leukemia Research</i> , 2017 , 61, 89-95	2.7	24
73	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. <i>Blood</i> , 2017 , 130, 1889-1897	2.2	101
72	Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea. 2017 , 58, 89-95		6
71	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. 2017 , 92, 187-195		26
70	The role of JAK2 inhibitors in MPNs 7 years after approval. <i>Blood</i> , 2018 , 131, 2426-2435	2.2	35
69	Genetic variation in IL28B (IFNL3) and response to interferon- α treatment in myeloproliferative neoplasms. 2018 , 100, 419-425		12
68	Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia. <i>HemaSphere</i> , 2018 , 2, e29	0.3	2

67	Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. 2018 , 103, e5-e9		11
66	SOHO State-of-the-Art Update and Next Questions: MPN. 2018 , 18, 1-12		4
65	Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. 2018 , 18, 788-795.e2		9
64	ASXL1 mutations in Chinese patients with essential thrombocythemia. 2018 , 15, 4149-4156		1
63	Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. <i>Leukemia Research</i> , 2018 , 71, 82-88	2.7	26
62	Polycythemia vera: diagnosis, clinical course, and current management. 2018 , 48, 698-710		5
61	Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. 2019 , 19, 579-584.e1		6
60	A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. 2019 , 33, 2974-2978		13
59	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019 , 134, 1498-1509	2.2	80
58	Thromboembolic events in polycythemia vera. 2019 , 98, 1071-1082		31
57	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. <i>Blood</i> , 2019 , 134, 2107-2111	2.2	9
56	Reducing the burden of MPN. <i>Blood</i> , 2019 , 134, 1483-1484	2.2	
55	Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia. 2019 , 3, 3724-3728		5
54	JAK2V617F but not CALR mutations confer increased molecular responses to interferon- α via JAK1/STAT1 activation. 2019 , 33, 995-1010		29
53	Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. 2020 , 20, 219-225		5
52	Myeloproliferative neoplasms. 2020 , 555-588		
51	Epidemiology of polycythemia vera in a Mexican population. 2020 , 13, 111-117		1
50	Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients. <i>International Journal of Hematology</i> , 2020 , 112, 631-639	2.3	0

49	Givinostat: an emerging treatment for polycythemia vera. 2020 , 29, 525-536		14
48	Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. 2021 , 106, 2397-2404		3
47	New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. 2020 , 21,		8
46	Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting. 2020 , 25, 247-257		3
45	Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study. 2020 , 10,		3
44	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. 2020 , 7, e196-e208		107
43	Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. 2021 , 192, 988-996		3
42	Germline genetic factors influence the outcome of interferon- α therapy in polycythemia vera. <i>Blood</i> , 2021 , 137, 387-391	2.2	5
41	Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. 2021 , 35, 1643-1660		10
40	Current Issues of Targeted Therapy of Polycythemia Vera. 2021 , 14, 355-360		0
39	Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. 2021 , 106, 316-322		4
38	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. 2021 , 11, 53		5
37	Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis. <i>International Journal of Hematology</i> , 2021 , 114, 342-354	2.3	3
36	Transformation of Polycythemia Vera to Pure Erythroid Leukemia. 2021 , 13, e16168		
35	IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia. 2021 , 1		1
34	Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. 2020 , 9, 2039-2051		11
33	Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. 2010 , 2,		3
32	Philadelphia-negative chronic myeloproliferative neoplasms. 2012 , 34, 140-9		9

- 31 Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. **2014**, 15, 1681-4 7
- 30 JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms. **2011**, 151-167
- 29 Therapy of Polycythemia Vera and Essential Thrombocythemia. **2011**, 97-115
- 28 Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy [Second-Line Options. **2012**, 119-129
- 27 Goal of Therapy and Monitoring the Response in Polycythemia Vera and Essential Thrombocythemia. **2012**, 85-92
- 26 Do We Need Biological Studies for Patient Management?. **2012**, 11-16
- 25 Patient Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms. **2012**, 47-55
- 24 Ongoing Clinical Trials in Myeloproliferative Neoplasms. **2012**, 215-232
- 23 Avances en el tratamiento de la policitemia vera. **2013**, 53-57
- 22 Tratamiento de la trombocitemia esencial. **2013**, 45-51
- 21 [Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera]. **2016**, 88, 69-77
- 20 Genomic Applications in Hematologic Oncology. **2019**, 269-287
- 19 Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies. **2021**, 365, 97-116 0
- 18 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 17 Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups. *HemaSphere*, **2020**, 4, e485 0.3 5
- 16 The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera. **2018**, 9, 56-66
- 15 Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.. **2022**, 9, e38-e48 5
- 14 Can the treatment of myeloproliferative neoplasms be both good and bad for you?. **2022**, 9, e3-e4

13	Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.. 2022 , 14,		
12	MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.. 2021 ,		0
11	Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.. 2022 ,		4
10	Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World.. <i>Frontiers in Oncology</i> , 2021 , 11, 797825	5.3	
9	Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.. <i>International Journal of Hematology</i> , 2022 , 1	2.3	1
8	European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. <i>HemaSphere</i> , 2022 , 6, e721	0.3	1
7	Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. <i>Leukemia Research</i> , 2022 , 119, 106903	2.7	
6	Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance. 2022 , 27, 813-819		
5	Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. 2022 , 123, 106962		0
4	A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.		1
3	Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.		0
2	Targeted Therapy for MPNs: Going Beyond JAK Inhibitors.		0
1	Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon- α multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). 2023 , 37, 924-928		0